Introduction: A benefit of carotid endarterectomy (CEA) within two weeks after carotid-related ischemic events was shown in multiple reports and guidelines *. However, a concrete timing and patient selection depending on neurologic impairment are debatable at present. Real risks of surgery and its influence on neurologic recovery in cases of Rankin 3 and more are debated. The aim of this study is an evaluation of our experience in early CEAs after the stroke. Methods: The cooperative experience of our clinics consists in 311 early CEA (male patients 65.9%, age 65.2AE7.5 years) within 14 days after acute ischemic event in 2010-2018. 22 (7.1%) patients underwent the systemic thrombolysis immediately after the admission. The main including criteria for surgery were stenoses of carotid bifurcation more than 60%, the neurological impairment up to 15 (NIHSS) or not exceeding Rankin 4, no signs of hemorrhage on CT and/or MR, and less than one third of hemisphere focus volume. The postoperative follow-up was evaluated on discharge, after 6 and 12 months. Results: The eversion CEA was performed in majority of cases (88.4%). The selective carotid shunt was applied in 7.7%, only in cases of critical clamping intolerance detected by NIRS .The serious adverse events immediate after the surgery were happened in 27 (8.7%) cases, including four postoperative strokes (1.2%), twelve hemorrhagic transformations (3.8%) and seven myocardial infarctions (2.3%). The common postoperative lethality amounted 2.9%. The neurologic improvement was detected in 75.8% within 10 days after the surgery, 87.5% within 6 months, and 89.7% within one year. No significant differences between patients with Rankin 0-2 and Rankin 3-4 were revealed in point of postoperative stroke (pŒ0.072) and lethality (pŒ0.054) amount or rehabilitation and recovery potency (pŒ0.107). Conclusion: We conceive, the CEA within first two weeks after carotid-related ischemic events is enough safe, effective and indicated as soon as possible for treatment of well selected patients, among other for patients with severe neurologic impairment. References